Drug Information for Simulect (Novartis Pharmaceuticals Corporation): INDICATIONS AND USAGE

Ads
  • Simulect®(basiliximab) is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine, USP (MODIFIED) and corticosteroids.

    The efficacy of Simulect for the prophylaxis of acute rejection in recipients of other solid organ allografts has not been demonstrated.

  • Drug Information Provided by National Library of Medicine (NLM).
Ads